Chicago: Monkeypox (MPV) Update

July 22, 2022
2022 MPV global outbreak: 15,848 Total Confirmed Cases identified in 72 countries

Source: CDC, Data as of 7/21/2022
In the U.S., 2,593 Total Confirmed MPV Cases identified in 46 States

Source: CDC, Data as of 7/21/2022
While the overall risk of MPV remains low, see a healthcare provider if you develop symptoms

- As of 7/21, a total of 197 Chicagoans have been diagnosed with monkeypox virus (MPV)
  - Most, but not all, have been in gay, bisexual, or other men who have sex with men (MSM)
  - Median age of 35 years (range: 22-66)
  - Spread occurs through tight-knit social networks

If you have a new or unexplained rash:
- Visit a healthcare provider or call 312-746-4835 to get connected to care
- Remind your provider that MPV is in the community
- Avoid sex or being intimate with anyone until you’ve been checked out
Widespread MPV TESTS available. TREATMENT exists.

- Testing capacity has ramped up and is now plentiful
  - Effective diagnostic testing capacity, up to 70,000-80,000 tests can be performed per week nationally
  - Now in public health and commercial labs
  - Swabs of lesions can be collected by any medical provider
  - Please get tested if you have symptoms!

- Treatment is available
  - FDA-approved antiviral medication (EU-IND tecovirimat - TPOXX)
  - Higher-risk patients
  - Prescribed through health care providers; still significant paperwork
MPV Vaccine

- A vaccine exists in limited quantities in the Strategic National Stockpile and the U.S. is acquiring more:
  - FDA-approved effective vaccines against MPV (JYNNEOS) help protect individuals who have been exposed to someone with MPV

- Chicago has received and already distributed about 5,000 vaccine doses to date
- 15,000 additional doses arriving from the federal government
- State has also redirected some of its federal vaccine supply to Chicago, given epicenter of outbreak is here
Ring Vaccination Strategy and Goal: Vaccinate **All Contacts of Cases**
YOU ARE ELIGIBLE FOR A MPV VACCINE IF YOU:

1. Had close physical contact with someone or an intimate partner who was diagnosed with MPV.

OR

2. Are a gay, bisexual or other (cis or trans) man who has sex with men.

AND

- Has intimate or sexual contact with other men in a social or sexual venue.
  OR
  Has given or received money or other goods or services in exchange for sex.
  OR
  Has intimate or sexual contact with multiple or anonymous partners.
At this time, MPV vaccine is NOT recommended for the general public, including same gender loving men, without other risk factors. As vaccine supply increases, guidance may evolve.

FOR MORE INFO, VISIT CHI.GOV/MONKEYPOX
Chicago is prioritizing first doses of JYNNEOS™ vaccine at this time

• At present, the top goal of immunization is outbreak control
• The 15,000 additional doses expected in Chicago will be used primarily as first doses to offer protection to more at-risk individuals
• Second doses will still be offered to immunocompromised individuals and to known contacts of MPV cases
• A second dose will be offered to others when vaccine supply improves
  • Biggest increase in protection is after the first dose
  • Delays in receiving the second dose do not affect the second dose immune response; 2nd dose vaccine labeled for “at least” 28 days later
• Same approach in other countries